BIO.News Newsletter

BIO’s Federal Government Relations team took a deep dive into President Biden’s proposed budget—here’s what you need to know. Plus, more COVID boosters are coming, and a new op-ed from BIO on the threat of AMR. (887 words, 4 minutes, 26 seconds)

A new policy paper explains why we need more funding for pandemic preparedness. Food shortages are coming – but biotech could help mitigate future ones, if we deploy solutions now. (644 words, 3 minutes, 19 seconds)

Beginning a new week with an explainer on Cures 2.0 and recent exhibits on the National Mall highlighting agriculture and women in STEM. Today, we’ll be watching to see what’s in President Biden’s FY23 budget. (604 words, 3 minutes, 1 second)

What lessons did we learn on supply chains and pandemic preparedness from COVID-19? How would allowing the federal government to exercise “march-in” rights harm university research and future innovation? We answer these questions. (647 words, 3 minutes, 14 seconds)

BIO member Gevo announced two deals that could bring us closer to net-zero aviation. Today is Lipoprotein(a) Awareness Day, highlighting genetic risk factors for heart disease. The Senate HELP Committee held a hearing yesterday on federal support for mental health care. (816 words, 4 minutes, 4 seconds)  

We take a closer look at the Feeding the Economy report on the economic impact of food and agriculture, while more U.S. Senators are speaking out about the CMS Alzheimer’s coverage proposal. (701 words, 3 minutes, 30 seconds)

On World Water Day, we launch a new season of the I am BIO Podcast with a look at the biggest threats to water and how biotech can address them. We also have details on the new Feeding the Economy report, released today, and why equitable access matters in colorectal cancer care. (758 words, 3 minutes, 47 seconds)

We’re starting a new week focused on fertilizer—here's why it’s such a big story and what biotech has to do with it. ICYMI, an agreement on a TRIPS waiver for vaccine IP was leaked last week, and we have the industry’s take. Plus, the Senate is taking up legislation on China competitiveness. (743 words, 3 minutes, 42 seconds)

It’s a health-heavy Friday, with a recap of what BIO’s Dr. Cartier Esham told a House panel yesterday about PDUFA and patient-centric drug development and a new letter urging HHS to reject a “march in” petition for a prostate cancer drug. (710 words, 3 minutes, 33 seconds)

There’s a lot to unpack from yesterday’s Senate Finance hearing on drug price controls—here are the facts (and a few tired myths). Also, BIO member LanzaTech testified yesterday on how the government can support biotech solutions and BIO’s Dr. Cartier Esham will testify today on PDUFA riders. (832 words, 4 minutes, 9 seconds)